REG - AstraZeneca PLC - Annual Financial Report <Origin Href="QuoteRef">AZN.L</Origin> - Part 12
08/03/2016 12:10
- Part 12: For the preceding part double click ID:nRSH4027Rk
governments and healthcare authorities, the outcome of negotiations with
third party payers, erosion of IP rights, including infringement by third
parties, failure to show a differentiated product profile and changes in
prescribing habits.As a result, we cannot be certain that compounds
currently under development will achieve success, and our ability to
accurately assess, prior to launch, the eventual efficacy or safety of a
new product once in broader clinical use can only be based on data
available at that time, which is inherently limited due to relatively
short periods of product testing and relatively small clinical study
patient samples. The commercialisation of biologics is often more complex
than for small molecule pharmaceutical products, primarily due to
differences in the mode of administration, technical aspects of the
- More to follow, for following part double click ID:nRSH4027RmRecent news on AstraZeneca
See all newsREG - AstraZeneca PLC - Tozorakimab met OBERON/TITANIA primary endpoints
AnnouncementREG - AstraZeneca PLC - Notification of Admission of Shares
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in EU for early gastric cancer
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementRCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
Announcement